论文部分内容阅读
表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)作为晚期非小细胞肺癌靶向治疗药物临床应用以来,已积累了大量的临床实验数据和临床应用经验[1～3]。目前,EGFR-TKI已被推荐为EGFR突变的晚期非小细胞肺癌的一线治疗方案,其批准上市应用于临床的靶向药物有吉非替尼(易瑞沙)、厄洛替尼(特罗凯)和埃克替尼(凯美纳)三个。凯美纳是目前中国惟一一个具有自主知识产权的肿瘤靶向治疗药物,上市一年多以来临床应用疗效与易瑞沙、特罗凯相当,且具有更高的安全性和治疗窗口[4]。现将我院2例埃克替尼诱导治疗晚期肺癌后成功实施手术的病例及经验报道如下。
Since the clinical application of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) as a targeted therapy for advanced non-small cell lung cancer, a large number of clinical experimental data and clinical experience have been accumulated [1-3]. Currently, EGFR-TKI has been recommended as a first-line treatment for EGFR mutation in advanced non-small cell lung cancer. The approved EGFR-TKIs are gefitinib (Iressa), erlotinib ) And Icotinib (Kemena) three. Kaimei Na is currently the only cancer-targeted drug with independent intellectual property rights in China. Since its launch in the market for more than a year, its efficacy has been comparable to that of Iressa and Tarceva with higher safety and therapeutic window [4] . Now in our hospital 2 cases of imatinib induction of advanced lung cancer after successful operation of the cases and experience reported below.